On Thursday, Shares of Merged Edison, Inc. (NYSE:ED), gained 0.44% to $61.57.
Con Edison has earned recognition for a smart grid innovation that lets customers install super-sized photovoltaic arrays and continue to receive reliable service.
The Solar Electric Power Association named Con Edison a winner of the Solar Power Player Award in the Investor Owned Utility category. The association assists utilities integrate solar energy into their portfolios.
“Our customers are seeking clean-energy options and ability to manage their costs,” said Robert Schimmenti, senior vice president, Electric Operations, for Con Edison. “One way we try to assist them meet those aims is by making it easy for them to turn to solar, a renewable source that is an important part of our state’s energy future.”
Merged Edison, Inc., through its auxiliaries, engages in regulated electric, gas, and steam delivery businesses in the United States. It offers electric services to about 3.4 million customers in New York City and Westchester County; gas to about 1.1 million customers in Manhattan, the Bronx, and parts of Queens and Westchester County; and steam to about 1,700 customers in parts of Manhattan.
Shares of Allergan PLC (NYSE:AGN), declined -0.46% to $293.56, during its last trading session.
Allergan plc and its partner Perrigo Company plc (NYSE: PRGO), declared that Allergan has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Applications for three Mucinex equivalent products.
- Mucinex DM Regular Strength (guaifenesin 600mg and dextromethorphan 30mg)
- Mucinex DM Maximum Strength (guaifenesin 1200mg and dextromethorphan 60mg)
- Mucinex Maximum Strength (guaifenesin 1200mg)
Perrigo will start shipments of the products to its retail and wholesale customers in the U.S in time for the 2016 cough and cold season. These products will be packaged and marketed as store brands which will give consumers high quality, value alternatives to these Mucinex® extended-release products.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands.
At the end of Thursday’s trade, Shares of Restoration Hardware Holdings Inc (NYSE:RH), lost -1.53% to $91.11.
RH (Restoration Hardware Holdings, Inc. - NYSE: RH), has launched its second quarter fiscal 2015 video presentation, which highlights the Company’s continued evolution and recent performance, in addition to further details on the forthcoming launch of RH Modern and RH Teen, on the RH Investor Relations website, ir.restorationhardware.com.
Restoration Hardware Holdings, Inc., together with its auxiliaries, engages in the retail of home furnishings. Its product categories comprise furniture, lighting, textiles, bathware, décor, outdoor and garden, tableware, and children’s furnishings.
Finally, Zimmer Biomet Holdings Inc (NYSE:ZBH), ended its last trade with -1.12% loss, and closed at $100.10.
Zimmer Biomet Holdings, declared that it will be participating in the Morgan Stanley 2015 Global Healthcare Conference at the Grand Hyatt in New York, on Thursday, September 17, 2015. Zimmer Biomet will present at 2:05 p.m. Eastern Time.
Zimmer Biomet Holdings, Inc., together with its auxiliaries, designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
